CareTrust REIT (CTRE) has been upgraded to a Buy rating following a recent price pullback. The company offers a unique combination of high yield and strong growth potential, with a projected 16% growth in funds from operations (FFO) per share by 2026. Its diversified platform, quality operators, and robust pipeline support this outlook, alongside a strong balance sheet and a 4% dividend yield. Despite trading at a premium valuation, demographic trends and disciplined acquisitions are expected to drive double-digit annualized returns for investors.
ARS Pharmaceuticals has seen its stock fall more than 65% due to significant commercialization difficulties. The company's new CEO plans to revitalize its FDA-approved no-needle epinephrine product, Neffy, through strict cost controls and focused phy...
Greg Abel, Warren Buffett's successor at Berkshire Hathaway, invested about $17 billion in Alphabet during Q2 2026, making it a core holding. This move aligns with Alphabet's strong fundamentals, including 24.2% revenue growth and a low valuation. Ab...
Taylor Devices' Q4 sales dropped to $8.95M from $15.56M last year, with full-year sales down to $41.65M from $46.29M. Net income also fell, impacted by delayed customer orders and weaker sales in non-aerospace markets. Despite this, the company maint...
Rocket One Inc. has introduced Swarm Stage AI, a platform designed to simulate large-scale drone swarms for U.S. military and defense use. This technology enables realistic training and evaluation against coordinated drone threats, addressing the gro...
Canadian GoldCamps Corp. has entered an agreement to acquire an initial 85% interest in the Stealthwall West gold project located in northeastern Québec. The acquisition involves issuing 3.6 million shares valued at $360,000 plus deferred considerati...
